Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Xtandi® (enzalutamide) – New indication
December 16, 2019 - Pfizer and Astellas Pharma announced the FDA approval of Xtandi (enzalutamide), for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).
